Leerink Partnrs Has Positive Outlook of XOMA FY2025 Earnings

XOMA Co. (NASDAQ:XOMA) – Leerink Partnrs raised their FY2025 earnings estimates for shares of XOMA in a report issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will earn ($0.60) per share for the year, up from their prior estimate of ($0.97). The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s FY2026 earnings at $0.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $5.81 EPS.

XOMA (NASDAQ:XOMA) last issued its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $104.00 target price on shares of XOMA in a research note on Wednesday. StockNews.com cut shares of XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th.

XOMA Trading Up 0.8 %

NASDAQ:XOMA opened at $21.06 on Thursday. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00. The stock has a market cap of $248.15 million, a P/E ratio of -6.05 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a 50-day simple moving average of $24.45 and a 200-day simple moving average of $27.20.

Hedge Funds Weigh In On XOMA

A number of institutional investors have recently modified their holdings of XOMA. BNP Paribas Financial Markets boosted its stake in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund raised its holdings in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,183 shares during the period. Bank of America Corp DE boosted its stake in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after buying an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in shares of XOMA during the fourth quarter worth about $206,000. 95.92% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.